Tuesday, February 07, 2017 10:39:37 AM
You bring up a very interesting and perhaps the most important topic to AMRN investors - WHAT TO DO 'WHEN' PPS SKYROCKETS FOLLOWING REDUCE-IT RESULTS.
Obviously at this point, there is no right or wrong answer as it will be strictly personal decisions, but I think it would benefit many people if others voiced their opinions on this. And by skyrocketing, I mean something like from $5 to $20, immediately thereafter.
One Correctional is that if results are great, I got no matter how high PPS jumps in one day, it will only be the beginning, for many reasons mentioned repeatedly on here. However, that's when everyone's personal situation comes in effect. Personally, even if I am 90% confident that PPS will skyrocket after skyrocketing from RI results (from $20 to $50), would I be willing he risked leaving so much money on the table? To me, the answer is no.
My hope is to develop a plan of action NOW, so that I don't act on impulse, when it occurs.
I'm thinking something like (re- PPS immediately following great RI results):
If < $10, don't touch;
If $10 - $15, sell 30%
If $15 - $25 sell 50%
If > $25 sell 60-70%
Obviously at this point, there is no right or wrong answer as it will be strictly personal decisions, but I think it would benefit many people if others voiced their opinions on this. And by skyrocketing, I mean something like from $5 to $20, immediately thereafter.
One Correctional is that if results are great, I got no matter how high PPS jumps in one day, it will only be the beginning, for many reasons mentioned repeatedly on here. However, that's when everyone's personal situation comes in effect. Personally, even if I am 90% confident that PPS will skyrocket after skyrocketing from RI results (from $20 to $50), would I be willing he risked leaving so much money on the table? To me, the answer is no.
My hope is to develop a plan of action NOW, so that I don't act on impulse, when it occurs.
I'm thinking something like (re- PPS immediately following great RI results):
If < $10, don't touch;
If $10 - $15, sell 30%
If $15 - $25 sell 50%
If > $25 sell 60-70%
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
